Holliger et al., “‘Diabodies’: Small Bivalent and Bispecific Antibody Fragments”, Proceedings of the National Academy of Science, U.S.A., vol. 90, Jul. 1993, pp. 6444-6448.* |
Clark et al., “Hybrid Antibodies for Therapy”, in Monoclonal Antibody Therapy, Edited by H. Waldmann, published by Karger, New York, 1988, pp. 31-49.* |
Bruggemann et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies”, Journal of Experimental Medicine, vol. 166, Nov., 1987, pp. 1351-1361.* |
Riechmann et al., “Reshaping Human Antibodies for Therapy”, Nature, vol. 332, Mar. 24, 1988, pp. 323-327.* |
Harris et al., “Therapeutic Antibodies-The Coming of Age”, Tibtech, vol. 11, Feb. 1993, pp. 42-44.* |
R. Dillman, “Antibodies as Cytotoxic Therapy”, Journal of Clinical Oncology, vol. 12, No. 7, Jul. 1994, pp. 1497-1515.* |
Brissinck et al., “Treatment of Mice Bearing BCL, Lymphoma With Bispecific Antibodies,” J. Immunol., 147(11):4019-4026 (1991). |
Chiswell et al., “Phage antibodies: Will new ‘coliclonal’ antiobodies replace monoclonal antibodies,” Trends in Biotechnology 10(3):80-84 (Mar. 1992). |
Condra J.H. et al., “Bacterial Expression of Antibody Fragments That Block Human Rhinovirus Infection of Cultured Cells,” J. Biol. Chem., 265(4):2292-2295 (Feb. 5, 1990). |
Griffiths, A.D. et al., “Human anti-self with high specificity from phage display libraries,” EMBO J., 12(2):725-734 (1993). |
Huston et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,” Methods in Enzymology, 203:46-89 (1991). |
Lodish et al., (Eds.) In Molecular Cell Biology, Third Edition, Scientific American Books, W.H. Freeman and Company, New York, Chapter 27, pp. 1304 (1995). |
Titus et al., “Human T Cells Targeted With Anti-T3 Cross-Linked To Antitumor Antibody Prevent Tumor Growth In Nude Mice,” J. Immunol., 138(11):4018-4022 (1987). |
Waldmann, H. (ed.): in Monoclonal Antibody Therapy, vol. 45, S. Karger AG, Basel (Switzerland), pp. 44-45 (1988). |
Weiner et al., “The Role of T Cell Activation in Anti-CD3 x Antitumor Specific Antibodiy Therapy,” J. Immunol., 152:2385-2392 (1994). |
Whitlow et al., “An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability,” Protein Engineering, 6(8):989-995 (1993). |